Helus Pharma (HELP) analyst forecast and price target
Analyst forecast
Consensus of 11 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Barclays | Initiated Coverage | Overweight | $35.00 | Sep 18, 2026 |
| TD Cowen | Maintained | Buy | $62.00 from $8.00 | Aug 20, 2026 |
| Wells Fargo | Initiated Coverage | Overweight | $16.00 | Jul 27, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $70.00 from $95.00 | Jul 9, 2026 |
| Canaccord Genuity | Maintained | Buy | $42.00 from $45.00 | Jul 1, 2026 |
| TD Cowen | Initiated Coverage | Buy | $8.00 | Apr 13, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $95.00 from $55.00 | Mar 2, 2026 |
Frequently asked questions
What is the price target for HELP stock?
The average 12-month analyst price target for Helus Pharma (HELP) is $37.67, with a high estimate of $62.00 and a low of $16.00, across 3 analysts.
Is HELP a buy, sell, or hold?
Analysts covering Helus Pharma currently average a Buy rating: 11 buy, 0 hold and 0 sell, from 11 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for HELP?
The average price target of $37.67 implies 269.42% upside from the last price of $10.20.
What is the latest analyst rating on HELP?
On Sep 18, 2026, Barclays initiated coverage of Helus Pharma at Overweight with a price target of $35.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.